Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
Date:7/29/2008

hat subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Idenix Pharmaceuticals' Contact:

Amy Sullivan (617) 995-9838

IDENIX PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(UNAUDITED)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Revenues:

Collaboration revenue -

related party $1,433 $18,674 $3,478 $43,025

Other revenue 159 1,058 157 1,513

Total revenues 1,592 19,732 3,635 44,538

Operating expenses (1):

Cost of sales 415 167 810 237

Research and

development 14,136 24,570 29,004 47,124

Selling, general and

administrative 6,651 19,837 14,972 35,677

Restructuring charges 37 ------ 297 ------

Total operating

expenses 21,239 44,574 45,083 83,038

Loss from operations (19,647) (24,842) (41,448) (38,500)

Investment income and

other income, net 485 1,802 1,425 3,780

Loss before income taxes (19,162) (23,040) (40,023) (34,720)

Income tax benefit 256 138 657 249

Net loss $(18,906) $(22,902) $(39,
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
2. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
5. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
6. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
7. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
8. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
9. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
10. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Yuma Regional Cancer Center Officially Opens ... comprehensive cancer care to Yuma, Arizona. , The ... has officially opened. A Mayo Clinic Care Network ... as open, semi-private and private infusion rooms, oncology ... Center, hematology, rehabilitation center, a pain management program ...
(Date:7/30/2014)... 30, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... and proprietary technologies are used to discover, develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... Dubinski as Vice President and Chief Financial Officer. ... and information technology operations for Dyadic and will ...
(Date:7/30/2014)... , July 30, 2014   Epic Sciences, ... and develops novel diagnostics to personalize and advance the ... of Gregory T. Lucier as chairman of ... and CEO of Life Technologies (formerly Invitrogen). Mr. Lucier ... Epic commercializes its circulating rare cell analysis platform with ...
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... SAN DIEGO , June 2 Neurocrine Biosciences, Inc. (Nasdaq: ... Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2010 Global ... in New York . , ... The live presentation for the Jefferies conference takes place on Wednesday, June ...
... International ... ... 2010 -- The International Food Information Council (IFIC) 2010 “ Consumer Perceptions of Food ... consider its potential benefits for reducing the impact of food and food production on ...
... Repligen Corporation (Nasdaq: RGEN ) announced today that it will ... Wednesday, June 9th, 2010 , before the market opens.  The Company President ... conference call and webcast on the same day at 10:00 a.m. EDT ... Company. , , , ...
Cached Biology Technology:Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference 2Interest in Environment & Sustainability Prevails in Food Technology Survey 2Interest in Environment & Sustainability Prevails in Food Technology Survey 3Interest in Environment & Sustainability Prevails in Food Technology Survey 4Interest in Environment & Sustainability Prevails in Food Technology Survey 5Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 3
(Date:7/30/2014)... York University is paving the way for a ... and military troops exposed to poisonous chemicalsparticularly those ... article in the current issue of the journal ... organophosphates, which are compounds commonly used in pesticides ... by NYU School of Engineering Associate Professor of ...
(Date:7/30/2014)... A deep-sea octopus protected and tended her eggs until ... published July 30, 2014 in the open-access journal ... Aquarium Research Institute and colleagues. , Octopuses typically have ... females protect and take care of their fertilized eggs ... eggs for 1 to 3 months, but little is ...
(Date:7/30/2014)... Everybody knows the shortest distance between two points is ... that sperm have been taking the familiar axiom to ... usually thought to be intense, with each racing for ... in some species, sperm form cooperative groups that allow ... , A new study, conducted by Heidi Fisher, ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Deep-sea octopus has longest-known egg-brooding period 2When cooperation counts 2When cooperation counts 3
... Researchers from Michigan State University,s departments of Electrical ... new wearable sensor network to assess a person,s physical ... engineering professor Subir Biswas, participants will wear three small, ... lower leg that during any physical activity will ...
... Research (SFBR) in San Antonio have found a gene ... in the blood as a result of a high-cholesterol ... developed at SFBR that has normal blood levels of ... low-cholesterol diet, but extremely elevated levels of LDL cholesterol ...
... Animal flocks, be it honeybees, fish, ants or birds, ... decisions at a moment,s notice, a phenomenon which has ... today, Wednesday 15 September, in New Journal of ... German Physical Society), uses a particle model to explain ...
Cached Biology News:Wearable sensor technology to measure physical activity 2Scientists find gene for high cholesterol in blood 2Understanding behavioral patterns: Why bird flocks move in unison 2
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... This reagent has been developed ... for the reduction of nonspecific background ... Traditional methods describe blocking peroxidase with ... hydrogen peroxide in combination with additional ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Biology Products: